Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 14 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

21%

3 trials in Phase 3/4

Results Transparency

0%

0 of 9 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
9(69.2%)
Phase 3
2(15.4%)
Phase 4
1(7.7%)
Phase 1
1(7.7%)
13Total
N/A(9)
Phase 3(2)
Phase 4(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials
NCT06751433Phase 1Recruiting

Evaluation of Clinical, Perceived and Instrumental Efficacy of a Scar Gel in Preventing Hypertrophic Scars

Role: lead

NCT06260007Phase 4Recruiting

Efficacy and Safety Study of Products Based on Tribulus Terrestris, L. in Men With Oligospermia

Role: lead

NCT06723340Not ApplicableCompleted

Dermatological Assessment of Primary Dermal Irritability Accumulated, Sensitization, Photoallergy and Photosensitization of a Scar Gel

Role: lead

NCT06353945Not ApplicableCompleted

Perceived Effectiveness of the Vaginal Moisturizer Investigational Product Under Normal Conditions of Use.

Role: lead

NCT05508230Not ApplicableCompleted

Evaluation of Cutaneous Acceptability and Perceived Effectiveness of a Nasal Spray (Health Care Products)

Role: lead

NCT05508243Not ApplicableCompleted

Dermatological Assessment of Primary Dermal Irritability Accumulated and Sensitization of Hyaluronic Nasal Spray

Role: lead

NCT04332445Not ApplicableCompleted

Dermatological Assessment of Primary Dermal Irritability Accumulated, Sensitization, Photoallergy and Phototoxicity.

Role: lead

NCT04247022Not ApplicableCompleted

Evaluation of Gynecological Acceptability of a Health Care Product

Role: lead

NCT04250623Not ApplicableCompleted

Dermatological Assessment of Photoallergy and Phototoxicity

Role: lead

NCT04248556Not ApplicableCompleted

Dermatological Assessment of Primary Dermal Irritability Accumulated and Sensitization

Role: lead

NCT04327947Not ApplicableCompleted

Evaluation of Gynecological Acceptability of 3 Health Care Products

Role: lead

NCT01365676Phase 3Unknown

GAMALINE®+HIPERICIN® for PMS Treatment and Vasomotor Symptoms

Role: collaborator

NCT01283568Unknown

Safety and Efficacy Study of Gamaline+Hipericin in PMS

Role: collaborator

NCT01481025Phase 3Unknown

Efficacy and Safety for Cimicifuga/Hypericum Product

Role: collaborator

All 14 trials loaded